ASAnna Solta

Anna Solta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Solta has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Proteomic analysis resulting from the comparison of entinostat sensitive versus resistant cell lines

  • Open Access

    Supplementary Table 2 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Proteomic analysis resulting from the comparison of SCLC cell lines showing synergistic or additive responses to entinostat and cisplatin therapy

  • Open Access

    Supplementary Figures 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

  • Open Access

    Small Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells

    by Büsra Ernhofer, Andreas Spittler, Franziska Ferk, Miroslav Mišík, Martha Magdalena Zylka, Lisa Glatt, Kristiina Boettiger, Anna Solta, Dominik Kirchhofer, Gerald Timelthaler, et al.


  • Open Access

    Small Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells

    by Buesra Ernhofer, Andreas Spittler, Franziska Ferk, Miroslav Mišík, Martha Magdalena Zylka, Lisa Glatt, Kristiina Boettiger, Anna Solta, Dominik Kirchhofer, Gerald Timelthaler, et al.

    Polystyrene micro-and nanoplastics (PS-MNPs) are emerging environmental pollutants with potential implications for human health. In this study, we used two different sizes of PS-MNPs (0.25 µm and 1 µm) on non-small cell lung cancer (A549, H460), small cell lung cancer (DMS53, H372), and normal lung epithelial (BEAS-2B) cells, as well as on human-derived lung organoids, to investigate the cytotoxic effects of PS particles. At lower concentrations (< 30 µg/cm 2 , equivalent to 50 µg/ml), neither PS-MPs nor PS-NPs did not interfere with cell viability or proliferation. Intracellular kinetic assays revealed that non-malignant (BEAS-2B) lung cells showed the strongest turnover of PS-NPs compared to malignant cells. Since PS-NPs exhibited more pronounced cellular effects, we focused further analyses on their impact. Furthermore, we observed significantly increased migration, prolonged S-phase arrest along with induced DNA damage, and oxidative stress in non-malignant (BEAS-2B) lung cells. Thus, our data suggest that BEAS-2B cells exhibit the highest sensitivity to PS-NPs. We also demonstrate that after PS-NP treatment, these cells displayed decreased base excision repair capacity and increased activation of survival pathways, including AKT and ERK phosphorylation. PS-NP internalization and increase of signal pathways were validated in a more physiological lung organoid setting. Altogether, our findings suggest that PS-NPs do not significantly affect the malignant behavior of cancer cells. However, they could promote tumor-like features in normal lung cells by inducing survival pathways, migration, and alterations in stress response mechanisms. Environmental Implications: This study investigates the effects of polystyrene micro-and nanoplastics (PS-MNPs) at environmentally relevant concentrations. The tested concentrations of PS-MNPs (0, 15, 30, and 60 µg/cm 2 , equivalent to 0, 25, 50, and 100 µg/ml) are commonly studied in the literature in lung cells. While these findings provide insights into cellular responses, the overall environmental impact of PS-MNPs remains limited at realistic exposure levels. Highlights: PS-MNPs are internalized into lung cells, with higher uptake in non-malignant cells. PS-NPs lead to increased migration, DNA damage, oxidative stress, and disturbed cell cycle progression. PS-NPs promote activation of survival pathways in non-malignant cells and lung organoids. Exposure of PS-NPs may cause potential implications for lung cancer development and progression.

  • Open Access

    Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer

    by K. Csende, B. Ferencz, K. Boettiger, Pozonec, A. Lantos, A. Ferenczy, O. Pipek, A. Solta, B. Ernhofer, V. Laszlo, et al.


  • Open Access

    Data from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Purpose:Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC.Experimental Design:The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays.Results:Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy.Conclusions:In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.

  • Open Access

    Data from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Purpose:Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC.Experimental Design:The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays.Results:Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy.Conclusions:In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.

  • Open Access

    Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Purpose: Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC. Experimental Design: The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays. Results: Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy. Conclusions: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.